Table 1.
Clinical characteristics of the 13,328 investigated colorectal-cancer patients
| No. of patients (%) |
||||
|---|---|---|---|---|
| Characteristic | Total (n = 13,328) | Cohort 1/1994–2013 (n = 3,945) | Cohort 2/2014–2019 (n = 9,383) | P-valuea |
| Sex | 0.010 | |||
| Male | 8,006 (60.1) | 2,303 (58.4) | 5,703 (60.8) | |
| Female | 5,322 (39.9) | 1,642 (41.6) | 3,680 (39.2) | |
| Ageb | <0.001 | |||
| <60 years | 5,589 (41.9) | 1,864 (47.2) | 3,725 (39.7) | |
| ≥60 years | 7,739 (58.1) | 2,081 (52.8) | 5,658 (60.3) | |
| Family history | <0.001 | |||
| No | 12,530 (94.0) | 3,629 (92.0) | 8,901 (94.9) | |
| Yes | 798 (6.0) | 316 (8.0) | 482 (5.1) | |
| Location | 0.099 | |||
| Right-sided colon | 3,087 (23.2) | 954 (24.2) | 2,133 (22.7) | |
| Left-sided colon | 4,034 (30.3) | 1,152 (29.2) | 2,882 (30.7) | |
| Rectum | 6,207 (46.6) | 1,839 (46.6) | 4,368 (46.6) | |
| Differentiation status | <0.001 | |||
| High | 1,539 (11.5) | 338 (8.6) | 1,201 (12.8) | |
| Moderate | 10,246 (76.9) | 3,002 (76.1) | 7,244 (77.2) | |
| Poor/undifferentiated | 1,543 (11.6) | 605 (15.3) | 938 (10.0) | |
| pT category | <0.001 | |||
| T1 | 1,248 (9.3) | 214 (5.4) | 1,034 (11.1) | |
| T2 | 1,821 (13.7) | 610 (15.5) | 1,211 (12.9) | |
| T3 | 6,446 (48.4) | 1,686 (42.7) | 4,760 (50.7) | |
| T4 | 3,813 (28.6) | 1,435 (36.4) | 2,378 (25.3) | |
| pN category | <0.001 | |||
| N0 | 8,036 (60.3) | 2,391 (60.6) | 5,645 (60.2) | |
| N1 | 3,434 (25.8) | 975 (24.7) | 2,459 (26.2) | |
| N2 | 1,858 (13.9) | 579 (14.7) | 1,279 (13.6) | |
| pM category | 0.057 | |||
| M0 | 11,464 (86.0) | 3,428 (86.9) | 8,036 (85.6) | |
| M1 | 1,864 (14.0) | 517 (13.1) | 1,347 (14.4) | |
| Clinical stage | <0.001 | |||
| I | 2,555 (19.1) | 664 (16.8) | 1,891 (20.1) | |
| II | 4,888 (36.7) | 1,523 (38.6) | 3,365 (35.9) | |
| III | 4,021 (30.2) | 1,241 (31.5) | 2,780 (29.6) | |
| IV | 1,864 (14.0) | 517 (13.1) | 1,347 (14.4) | |
| Pathologic subtype | <0.001 | |||
| Adenocarcinoma | 11,744 (88.1) | 3,486 (88.4) | 8,258 (88.0) | |
| MA and SRCC | 1,087 (8.2) | 438 (11.1) | 649 (6.9) | |
| Othersc | 497 (3.7) | 21 (0.5) | 476 (5.1) | |
| Operation | <0.001 | |||
| Radical | 12,554 (94.2) | 3,600 (91.3) | 8,954 (95.4) | |
| Palliative | 774 (5.8) | 345 (8.7) | 429 (4.6) | |
| Surgical margin | 0.121 | |||
| Negative | 12,805 (96.1) | 3,774 (95.7) | 9,030 (96.2) | |
| Positive | 823 (3.9) | 171 (4.3) | 353 (3.8) | |
| Chemotherapy | <0.001 | |||
| No | 7,337 (55.0) | 2,323 (58.9) | 5,014 (53.4) | |
| Yes | 5,991 (45.0) | 1,622 (41.1) | 4,369 (46.6) | |
a
Comparisons are made between Cohort 1 and Cohort 2.
b
The mean ± standard deviation age at diagnosis is 61.3 ± 13.4 years for all patients; the range is 16–101 years.
c
Other pathologic subtypes include gastrointestinal stromal tumors, adenosquamous carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, malignant melanoma, lymph hematopoietic neoplasms, and gastrointestinal mesenchymal tumors.
MA, mucinous adenocarcinoma; SRCC, signet-ring cell carcinoma.